title: Treatment of primary and metastatic liver cancer using an implantable chemoinfusion pump.
abstract: Twenty evaluable patients with primary or secondary neoplastic liver involvement received FUDR (0.2 to 0.3 mg/kg per day) by continuous infusion to the hepatic artery for 14 days, every 4 weeks, through a surgically implanted Infusaid (USA) pump. In addition to FUDR, MMC (15 mg/m2 every 6 to 8 weeks) was given to 14 patients with colorectal cancer and one patient with breast cancer, and ADR, (40 mg/m2 every 4 to 6 weeks) was given to 5 patients with hepatocellular carcinoma. MMC and ADR were given as a bolus injection, through the pump sideport. Radiation therapy to the liver (2,000 rads in fractions of 180 to 200 rads each) was given to eight patients with colorectal carcinoma. In total, the 20 patients received 218 months of treatment and 580 injections. The overall remission rate (complete, partial and minor response) was 55%; one patient with a colorectal carcinoma achieved a CR and seven patients (35%) a PR; three patients (15%) had a MR, and in eight patients (40%) stabilization of disease was observed. Overall median survival was 12 months: 15.5 months for colorectal cancer patients and 7.5 months for patients with hepatocellular carcinoma. Toxicity consisted mainly of chemical hepatitis, mild to severe peptic disease and sclerosing cholangitis. Hematological toxicity was not observed. These data suggest that chemotherapy through the hepatic artery, while still experimental, may be considered for selected patients with tumor confined to the liver.
authors.affiliation: Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: T
authors.initials: T
authors.lastname: Peretz
authors.forename: H R
authors.initials: HR
authors.lastname: Freund
authors.forename: R
authors.initials: R
authors.lastname: Isacson
authors.forename: A
authors.initials: A
authors.lastname: Ben-Yosef
authors.forename: E
authors.initials: E
authors.lastname: Goldin
authors.forename: L
authors.initials: L
authors.lastname: Haskel
authors.forename: R
authors.initials: R
authors.lastname: Chisin
authors.forename: S
authors.initials: S
authors.lastname: Biran
authors.forename: A L
authors.initials: AL
authors.lastname: Durst
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D003110:Colonic Neoplasms / Q000401:mortality; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007260:Infusion Pumps; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged
chemical_list: D005467:Floxuridine